Vatreptacog alfa from conception to clinical proof of concept

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 3, 2012, Pages 274-281

  Persson, Egon ^a   Olsen, Oleh ^a   Bjrn, Srene ^a   Ezban, Mirella ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

factor VIIa variant; factor X activation; intrinsic activity; tissue factor independent capability; vatreptacog alfa

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN; TRANEXAMIC ACID;

BLOOD CLOTTING; CHO CELL; CONCEPTION; DISEASE MODEL; DRUG CLEARANCE; DRUG CONFORMATION; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERANCE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRIN CLOT; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MASS SPECTROMETRY; MUTAGENESIS; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; THROMBOCYTE ACTIVATION;

ANIMALS; CHO CELLS; CRICETINAE; FACTOR VIIA; GENETIC ENGINEERING; HEMOPHILIA A; HUMANS; MOLECULAR STRUCTURE; RECOMBINANT PROTEINS;

EID: 84860174663     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1302442     Document Type: Review

References (51)

1. Astermark J. Treatment of the bleeding inhibitor patient. Semin Thromb Hemost: 2003; 29 1 77 86
2. Higashi S, Nishimura H, Aita K, Iwanaga S. Identification of regions of bovine factor VII essential for binding to tissue factor. J Biol Chem: 1994; 269 29 18891 18898 (Pubitemid 24226203)
3. Ruf W, Dickinson CD. Allosteric regulation of the cofactor-dependent serine protease coagulation factor VIIa. Trends Cardiovasc Med: 1998; 8 8 350 356 (Pubitemid 28565199)
4. Monroe DM, Key NS. The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking. J Thromb Haemost: 2007; 5 6 1097 1105 (Pubitemid 46902106)
5. Olsen OH, Persson E. Cofactor-induced and mutational activity enhancement of coagulation factor VIIa. Cell Mol Life Sci: 2008; 65 6 953 963
6. Pedersen AH, Nordfang O, Norris F., et al. Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. J Biol Chem: 1990; 265 28 16786 16793 (Pubitemid 120013485)
7. Higashi S, Nishimura H, Fujii S, Takada K, Iwanaga S. Tissue factor potentiates the factor VIIa-catalyzed hydrolysis of an ester substrate. J Biol Chem: 1992; 267 25 17990 17996
8. Berntorp E. Importance of rapid bleeding control in haemophilia complicated by inhibitors. Haemophilia: 2011; 17 1 11 16
9. Persson E, Kjalke M, Olsen OH. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci U S A: 2001; 98 24 13583 13588 (Pubitemid 33115941)
10. Pike ACW, Brzozowski AM, Roberts SM, Olsen OH, Persson E. Structure of human factor VIIa and its implications for the triggering of blood coagulation. Proc Natl Acad Sci U S A: 1999; 96 16 8925 8930 (Pubitemid 29374684)
11. Banner DW, D'Arcy A, Chne C., et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature: 1996; 380 6569 41 46 (Pubitemid 26076234)
12. Persson E. Variants of recombinant factor VIIa with increased intrinsic activity. Semin Hematol: 2004; 41 1, Suppl 1 89 92 (Pubitemid 38182723)
13. Fehlhammer H, Bode W, Huber R. Crystal structure of bovine trypsinogen at 1-8 A resolution. II. Crystallographic refinement, refined crystal structure and comparison with bovine trypsin. J Mol Biol: 1977; 111 4 415 438 (Pubitemid 8090356)
14. Petrovan RJ, Ruf W. Role of zymogenicity-determining residues of coagulation factor VII/VIIa in cofactor interaction and macromolecular substrate recognition. Biochemistry: 2002; 41 30 9302 9309 (Pubitemid 34810004)
15. Margaritis P, Roy E, Faella A., et al. Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo. Blood: 2011; 117 15 3974 3982
16. Petrovan RJ, Ruf W. Residue Met(156) contributes to the labile enzyme conformation of coagulation factor VIIa. J Biol Chem: 2001; 276 9 6616 6620
17. Persson E, Olsen OH. Assignment of molecular properties of a superactive coagulation factor VIIa variant to individual amino acid changes. Eur J Biochem: 2002; 269 23 5950 5955 (Pubitemid 35425592)
18. Bjelke JR, Olsen OH, Fodje M., et al. Mechanism of the Ca2 + -induced enhancement of the intrinsic factor VIIa activity. J Biol Chem: 2008; 283 38 25863 25870
19. Rand KD, Andersen MD, Olsen OH., et al. The origins of enhanced activity in factor VIIa analogs and the interplay between key allosteric sites revealed by hydrogen exchange mass spectrometry. J Biol Chem: 2008; 283 19 13378 13387
20. Sommer C, Norbert Jrgensen P, Salanti Z, Clausen JT, Jensen LB. Immunogenicity of novel recombinant human activated factor VII analogues on factor VII neonatally-tolerized rats. Thromb Haemost: 2007; 98 4 721 725 (Pubitemid 47555061)
21. Ghosh S, Ezban M, Persson E, Pendurthi U, Hedner U, Rao LVM. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. J Thromb Haemost: 2007; 5 2 336 346 (Pubitemid 46139459)
22. Allen GA, Persson E, Campbell RA, Ezban M, Hedner U, Wolberg AS. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol: 2007; 27 3 683 689
23. He S, Ezban M, Bark N, Persson E, Hedner U. Fibrin gel structure obtained with a FVIIa analogue with enhanced FX-activating potential in haemophilia. Thromb Haemost: 2009; 102 4 790 792
24. Gray LD, Hussey MA, Larson BM., et al. Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma. Thromb Res: 2011; 128 6 570 576
25. Lisman T, Mosnier LO, Lambert T., et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood: 2002; 99 1 175 179
26. Lisman T, de Groot PG, Lambert T, Rjkjaer R, Persson E. Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A. J Thromb Haemost: 2003; 1 10 2175 2178
27. Rea CJ, Foley J, Ezban M, Bevan D, Sorensen B. rFVIIa analogue and rFVIIa enhance clot stability more than FVIII in haemophilia A. J Thromb Haemost: 2011; 9 02 P-TU-503 (abstract)
28. Aljamali MN, Kjalke M, Hedner U, Ezban M, Tranholm M. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions. Haemophilia: 2009; 15 6 1318 1326
29. Srensen B, Persson E, Ingerslev J. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol: 2007; 137 2 158 165 (Pubitemid 46474712)
30. Brophy DF, Martin EJ, Nolte ME, Kuhn JG, Carr ME Jr. Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients. Haemophilia: 2007; 13 5 533 541 (Pubitemid 47337993)
31. Brophy DF, Martin EJ, Nolte ME, Kuhn JG, Barrett JC, Ezban M. Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A. Blood Coagul Fibrinolysis: 2010; 21 6 539 546
32. Brophy DF, Martin EJ, Barrett JC., et al. Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays. Blood Coagul Fibrinolysis: 2011; 22 6 541 546
33. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol: 1997; 99 3 542 547 (Pubitemid 27519853)
34. Kjalke M, Kjellev S, Rojkjaer R. Preferential localization of recombinant factor VIIa to platelets activated with a combination of thrombin and a glycoprotein VI receptor agonist. J Thromb Haemost: 2007; 5 4 774 780 (Pubitemid 46563577)
35. Hoffman M, Volovyk Z, Persson E, Gabriel DA, Ezban M, Monroe DM. Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity. J Thromb Haemost: 2011; 9 4 759 766
36. Persson E, Bolt G, Steenstrup TD, Ezban M. Recombinant coagulation factor VIIafrom molecular to clinical aspects of a versatile haemostatic agent. Thromb Res: 2010; 125 6 483 489
37. Tranholm M, Kristensen K, Kristensen AT, Pyke C, Rjkjaer R, Persson E. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood: 2003; 102 10 3615 3620 (Pubitemid 37409379)
38. Holmberg HL, Lauritzen B, Tranholm M, Ezban M. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice. J Thromb Haemost: 2009; 7 9 1517 1522
39. vlisen K, Kristensen AT, Valentino LA, Hakobyan N, Ingerslev J, Tranholm M. Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice. J Thromb Haemost: 2008; 6 6 969 975 (Pubitemid 351689919)
40. Whinna HC, Monroe DM. A novel murine hemostasis model: studies on recombinant factor VIIa and NN1731. J Thromb Haemost: 2009; 7 02 PP-MO-392 (abstract)
41. Lauritzen B, Hedner U, Johansen PB, Tranholm M, Ezban M. Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats. J Thromb Haemost: 2008; 6 5 804 811 (Pubitemid 351524541)
42. Lauritzen B, Tranholm M, Ezban M. rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats. J Thromb Haemost: 2009; 7 4 651 657
43. Hoffman M, Harger A, Lenkowski A, Hedner U, Roberts HR, Monroe DM. Cutaneous wound healing is impaired in hemophilia B. Blood: 2006; 108 9 3053 3060
44. McDonald A, Hoffman M, Hedner U, Roberts HR, Monroe DM. Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. J Thromb Haemost: 2007; 5 8 1577 1583 (Pubitemid 47091394)
45. Hoffman M, Brock J, Ezban M, Monroe DM. An analogue of factor VIIa improves wound healing in hemophilia B mice. J Thromb Haemost: 2011; 9 02 P-MO-550 (abstract)
46. Agers H, Brophy DF, Pelzer H., et al. Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients. J Thromb Haemost: 2011; 9 2 333 338
47. Petersen LC, Karpf DM, Agers H., et al. Intravascular inhibition of factor VIIa and the analogue NN1731 by antithrombin. Br J Haematol: 2011; 152 1 99 107
48. Agers H, Kristensen NR, stergaard H., et al. Clearance of rFVIIa and NN1731 after intravenous administration to Beagle dogs. Eur J Pharm Sci: 2011; 42 5 578 583
49. Mss J, Scharling B, Ezban M, Mller Srensen T. Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects. J Thromb Haemost: 2009; 7 2 299 305
50. Fridberg MJ, Hedner U, Roberts HR, Erhardtsen E. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagul Fibrinolysis: 2005; 16 4 259 266 (Pubitemid 40705047)
51. De Paula E, Kavakli K, Mahlangu J., et al, on behalf of 1804 (adept 1) Investigators. Clinical and laboratory results from adeptTM 1, a phase 2 trial investigating the use of recombinant activated FVII analogue in congenital haemophilia patients with inhibitors. J Thromb Haemost: 2012; 10 1 81 89